13F filing recap · Q4 2025
What did Patient Capital Management buy in Q4 2025?
Reported stock-position changes between this filing and the previous one.
Stock value
$2.59B
Positions
40
Estimated turnover
17.1%
Turnover is a proxy: verified trade-origin share changes valued at period-end and divided by average reported stock value. SEC holdings reports do not disclose execution dates or prices. Corporate actions and unreconciled activity are excluded.
Quarter in review
Patient Capital Management opened new positions in Chime Financial and Fiserv, while exiting Angi, Kosmos Energy, and Strategy. The firm substantially increased its Biogen stake and trimmed Alibaba and SoFi Technologies significantly. Other notable moves included adding to Norwegian Cruise Line, IAC, Crocs, Mattel, and the Fidelity Wise Origin Bitcoin Fund, while reducing Precigen, Expedia, Delta Air Lines, and UBS Group.